An interventional study of TEMMA Endovascular Treatment in Migraine Disorders, Refractory Migraine and Chronic Migraine, sponsored by Cortex Neurovascular. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Cortex Neurovascular · Not applicable, Interventional, and Treatment
The study was not initiated. IRB review determined the study would require an investigational device exemption (IDE), and the sponsor elected not to proceed because resources were not available. No subjects were enrolled.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 697 studies in Migraine Disorders with a site in United States — 92 open to participants now, 114 under way, 27 of them phase 3. Migraine Disorders · United States.
Among the 697 studies in Migraine Disorders with a site in United States, this one is the 591st largest by enrollment of the 610 interventional ones that give a count, is the only one that started in 2028, is one of 204 with no phase, and was the 663rd registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →92 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
University of Colorado, Denver · Sites in United States
Ages 12–17
Columbia University · Sites in United States
Ages 18–55
TriGemX Bio, Inc. · Sites in United States
Ages 18–75
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
697 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 113 · Phase 3 151 · Phase 4 101
First in 1999; this study’s year is marked. 1 started in 2028.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 78 across the 610 interventional studies, 195 across the 84 observational. Of the 528 that completed or were terminated, 305 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
345 of 697 have an industry lead sponsor. The 10 most frequent:
Cortex Neurovascular is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Cortex Neurovascular has 2 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
47 of the studies in Migraine Disorders with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07645924Phase 3TriGemX Bio, Inc.A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | 2027-02 |
| NCT05598723Phase 3Naval Medical Center Camp LejeuneBOTOX® vs. XEOMIN® for Chronic Migraine | 2027-02-24 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
Add all 47 to your calendar (.ics) → With an account.
Among the 697 studies in Migraine Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1).
This is an investigator-initiated, prospective, single-site, open-label pilot study designed to evaluate the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment approach targeting meningeal arterial contributors to migraine symptoms. TEMMA represents a structured clinical program applying endovascular treatment principles to patients with refractory migraine.
Participants undergo a baseline assessment period that includes prospective headache diary collection, capturing headache presence, pain intensity, and acute medication use, along with baseline migraine-related disability and quality-of-life assessments. Endovascular treatment is performed as part of the TEMMA program using FDA-cleared devices in accordance with institutional clinical practice. Procedural techniques, vessel selection, materials, adjunctive assessments, and treatment sequencing are determined by the treating physician and are not fully standardized within this pilot study.
Adjunctive assessments, which may include intra-procedural physiologic or pharmacologic evaluations, may be performed at the discretion of the treating physician to inform clinical decision-making but are not required for study participation and are not used as mandatory eligibility criteria.
Participants are followed longitudinally with serial headache diary data and standardized patient-reported outcome measures collected at predefined intervals through 12 months following treatment. The primary endpoint is change in monthly headache days compared with baseline. Secondary endpoints include changes in headache intensity, acute medication use, migraine-related disability, quality of life, and durability of symptom improvement.
Safety is monitored throughout the study through adverse event reporting with independent physician oversight.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of migraine (with or without aura)
-≥8 headache days per month
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with refractory migraine undergo the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy addressing meningeal arterial contributors to migraine. Treatment is performed using FDA-cleared devices per institutional clinical practice. Procedural details and adjunctive assessments are individualized and not dictated by the study protocol. Outcomes are evaluated using within-subject comparison to baseline.
Device: TEMMA Endovascular Treatment
Endovascular treatment targeting meningeal arterial contributors to migraine performed as part of the TEMMA procedure (Targeted Embolization for Migraine Management) using FDA-cleared devices. Procedural techniques and adjunctive assessments are individualized at the discretion of the treating physician and are not standardized within the study.
Change in Monthly Headache Days Post-Embolization
Change from baseline in the number of headache days per month following bilateral middle meningeal artery coil embolization, assessed via SMS-based headache diary.
Time frame: Baseline to 12 months post-embolization
Change in Headache Intensity
Change from baseline in average headache pain intensity (0-10 scale), assessed via SMS-based headache diary.
Time frame: Baseline to 12 months post-embolization
Change in Acute Medication Use
Change from baseline in the number of days with acute migraine medication use per month.
Time frame: Baseline to 12 months post-embolization.
Change in Migraine Disability Assessment (MIDAS) Score
Change from baseline in MIDAS score, a validated measure of migraine-related disability.
Time frame: Baseline to 3 months (assessed at 1, 3, 6, and 12 months).
Change in Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Score
Change from baseline in MSQ v2.1 score, a validated measure of migraine-specific quality of life.
Time frame: Baseline to 3 months (assessed at 1, 3, 6, and 12 months).
Time to Symptom Recurrence Following Lidocaine Testing
Duration of symptom improvement (time to return to baseline headache frequency/intensity) after bilateral MMA lidocaine testing.
Time frame: Up to 4 weeks post-lidocaine testing.
Time to Symptom Recurrence Following Embolization
Duration of symptom improvement (time to return to baseline headache frequency/intensity) after bilateral MMA coil embolization.
Time frame: Up to 12 months post-embolization.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2028; primary completion for Mar 2030, 24 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Mar 2026 → Mar 2028, primary completion Mar 2027 → Mar 2030 and completion Mar 2028 → Mar 2032.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
The study was not initiated. IRB review determined the study would require an investigational device exemption (IDE), and the sponsor elected not to proceed because resources were not available. No subjects were enrolled.
The study was not initiated. IRB review determined the study would require an investigational device exemption (IDE), and the sponsor elected not to proceed because resources were not available. No subjects were enrolled.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cortex Neurovascular